Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ACC-001 with QS-21 in Japanese subjects with mild to moderate Alzheimer's disease
jRCT2080221374Phase 2
- Sponsor
- Pfizer
- Start
- Feb 2011
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of vanutide cridificar in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Safety and tolerability of ACC-001 with QS-21 and Immunogenicity of ACC-001 with QS-21.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080221374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221374.